Infliximab, azathioprine, or combination therapy for Crohn's disease - Wikidata - awgldk - TriplyDB

Infliximab, azathioprine, or combination therapy for Crohn's disease

Infliximab, azathioprine, or combination therapy for Crohn's disease

http://www.wikidata.org/entity/Q56988763

about

Epidemiology and clinical course of Crohn's disease: results from observational studies Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease Vedolizumab for the treatment of ulcerative colitis and Crohn's disease Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease Optimal delivery of follow-up care after surgery for Crohn's disease: current perspectives Inflammatory bowel disease surgery in the biologic era Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease The clinical potential of etrolizumab in ulcerative colitis: hypes and hopes Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients Implementation of the simple endoscopic activity score in crohn's disease Selective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumab Fecal calprotectin in inflammatory bowel disease Elderly patients and inflammatory bowel disease How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Crohn's disease: a clinical update Pharmacologic therapy for inflammatory bowel disease refractory to steroids Patient considerations in the management of ulcerative colitis - role of vedolizumab Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer Use of thiopurines in inflammatory bowel disease Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial Mucosal healing and deep remission: what does it mean?Therapeutic drug monitoring in inflammatory bowel disease Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data A review of the impact of biologics on surgical complications in Crohn's disease Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future Impact of medical therapies on inflammatory bowel disease complication rate Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists

P2860

Q22241217-76D66A33-DC39-4180-82A2-AD3DE89CC882 Q22305935-A26CAD4E-6920-4183-9639-A71EB88832E3 Q24185835-FD3157FF-ABFB-4919-AC58-3978E694E94C Q24186291-F9FAE4DA-8DA5-4ADD-AABB-614D8EBC5A27 Q24188040-D6AB8CB9-B4BA-4558-9E5C-8E0330B1840C Q24197676-A8C601C3-B2CD-4397-B26F-44196CF36A7D Q24630083-31BF0CE3-CD5D-4EE1-A66B-D36E5D456826 Q24631869-3D70ED6B-83E3-437B-8625-12D3C705F069 Q26740356-2D60E1F6-E2A0-46BF-AFEB-9993E2534F79 Q26745627-D911FC9B-1321-42EC-86F0-C067987EE47C Q26745721-73FF7F3A-DB3B-48F2-B248-933D02522620 Q26745725-57A902F9-2230-443F-B78E-5D4C64BF435A Q26748630-16AFAECF-B127-4D8E-AF7B-DC20C7EC22DA Q26749323-2C5A53A0-E71F-4060-8699-C9608C202C60 Q26750456-F4313073-7141-4A46-AB38-5BF34EE8117A Q26766527-1C2167D3-5470-4A47-B771-6BEB41FD4E73 Q26768270-9FB2B95C-730F-4A9C-A606-6726B06A6263 Q26777409-2CF5A85B-97C1-4821-AC29-34F76D23D93D Q26777429-B8015569-5293-4FE2-BA93-173BD0B8302F Q26777696-44762916-79CD-4ECE-8CB8-57A52D59315F Q26796415-BAF0FEF9-0233-4B39-A198-A54E4FC370E7 Q26796432-8BE7D2A2-F17D-426A-A48B-52B02705FBB3 Q26822029-B7A041AC-EE63-464E-B916-3DDFF15DA2F5 Q26823237-E01A59EF-330B-45E5-889C-BDFB1A62CE2D Q26824662-05DBD834-3B49-45FB-A29B-5903F723CDB8 Q26825174-C592BED7-A12C-4703-A0A8-242187E5EE44 Q26827444-02C38E02-5F42-43DB-9A71-5B610D2CB67E Q26829488-16C38C5D-3AFC-4C34-8DB1-F2B8FD209EFC Q26852447-3C11F93A-A322-4BC2-AA43-D76454DC8991 Q26852729-90A77097-E88B-462C-8F20-2152FFD85D2C Q26864906-03F23C8B-2B77-4C9A-953C-C7DA101A7B58 Q26865009-8DB78B22-EAF1-4DF0-96EE-1E1473C19AC9 Q26866940-2AD8748D-E00C-4A95-8037-563DD9E4234F Q26991673-3479A08C-A135-4476-B7D0-C9DB11A68737 Q26992012-F99BA8A9-ABEB-4C0A-BDD8-2E3AE480102F Q26995479-5D128B1D-A044-4430-BE61-4927E34797A7 Q26996518-3ACAAF37-2D2F-46E0-93C7-93B89E88C799 Q26996550-368CFEE9-50DB-4FE6-9248-495D8985D824 Q26996946-640A8C3F-6180-427B-B053-70A77D86DF15 Q26999078-95B569E3-680E-478C-833D-CB43314291C3

P2860

Infliximab, azathioprine, or combination therapy for Crohn's disease

http://www.wikidata.org/entity/Q56988763

description

article

@en

im April 2010 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у квітні 2010

@uk

name

Infliximab, azathioprine, or combination therapy for Crohn's disease

@en

Infliximab, azathioprine, or combination therapy for Crohn's disease

@nl

type

label

Infliximab, azathioprine, or combination therapy for Crohn's disease

@en

Infliximab, azathioprine, or combination therapy for Crohn's disease

@nl

prefLabel

Infliximab, azathioprine, or combination therapy for Crohn's disease

@en

Infliximab, azathioprine, or combination therapy for Crohn's disease

@nl

P1433

Q56988763-55F51B1F-7DB8-4095-8545-35683F8786EA

P1476

Q56988763-2266FEA4-5260-4C98-AD1D-CBC497E5AA0F

P2093

Q56988763-18ED2CAD-C689-4A4B-BBFC-9396AC03C011

Q56988763-58ED29E3-DCCB-46CD-A4BB-FE0DBE1722A1

Q56988763-7B7FA473-C4B6-4476-BB1E-1128C464C5AC

Q56988763-8A1202CF-7522-47E8-9275-572CEA7D00B6

Q56988763-92A7D25D-AFBF-4A48-B88D-AE6873BEDC76

Q56988763-9663806D-F451-4F60-8243-999377285F27

Q56988763-9900837D-1DC4-4A27-81D0-83F70C12A9B3

Q56988763-A1141F3B-1B68-4233-9545-FC6E9C77E663

Q56988763-C26D83C3-012E-4B1F-B772-155F3461A289

Q56988763-F9CBAAF4-342E-45E7-AA19-FF31BE45C524

P304

Q56988763-6ED8A08C-44DF-4E36-B9A6-56DE3C0EC435

P31

Q56988763-A525577E-BB9E-401D-B727-C9327339910B

P356

Q56988763-13927C2E-5A24-48A8-8BBC-25789D70D428

P407

Q56988763-AAA1FF2D-1302-49E8-9AAC-5031D147D05B

P433

Q56988763-8A3F813A-022E-4A26-AA34-59B700D6498B

P478

Q56988763-0BA8260A-98AB-4CD0-8A1B-931F9FE8DB8A

P50

Q56988763-ABA9667E-F30C-4DCB-8542-DCA7B96F71B5

Q56988763-B387DAC6-A323-45B7-AFA9-29CA17D0A93E

Q56988763-E868CDE5-6C3B-4266-8D24-A5E41923776C

P577

Q56988763-57AF069E-9D35-4299-BC83-4268FA6E5346

P698

Q56988763-7BCB2935-C3D5-48AD-AE3F-B947872A290E

P356

P1433

The New England Journal of Medicine

P1476

Infliximab, azathioprine, or combination therapy for Crohn's disease

@en

P2093

Asher Kornbluth

http://www.w3.org/2001/XMLSchema#string

C Janneke van der Woude

http://www.w3.org/2001/XMLSchema#string

Daniel Rachmilewitz

http://www.w3.org/2001/XMLSchema#string

Delma L Broussard

http://www.w3.org/2001/XMLSchema#string

Geert D'Haens

http://www.w3.org/2001/XMLSchema#string

Gerassimos J Mantzaris

http://www.w3.org/2001/XMLSchema#string

Kezhen L Tang

http://www.w3.org/2001/XMLSchema#string

Robert H Diamond

http://www.w3.org/2001/XMLSchema#string

Simon Lichtiger

http://www.w3.org/2001/XMLSchema#string

Walter Reinisch

http://www.w3.org/2001/XMLSchema#string

P304

1383-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA0904492

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Frédéric Colombel

William Jeffery Sandborn

P577

2010-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20393175

http://www.w3.org/2001/XMLSchema#string